More Like This

Business Wire logo

TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy

ASTRAZENECA’S IMFINZI (DURVALUMAB) RECOMMENDED BY NICE FOLLOWING MHRA APPROVAL AS FIRST IMMUNOTHERAPY IN COMBINATION WITH PERIOPERATIVE CHEMOTHERAPY IN RESECTABLE GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION CANCER

Capivasertib approved to treat patients with advanced breast cancer

PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

Business Wire logo

European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer

Business Wire logo

BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy

Business Wire logo

BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma

Ocrelizumab approved as an injection to treat multiple sclerosis in adults